纳武利尤单抗致恶性黑色素瘤相关性系统性硬皮病。
Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.
机构信息
Service de Rhumatologie, Centre Hospitalier Universitaire de Limoges Dupuytren 2, Limoges, France;
Service de Dermatologie, Centre Hospitalier Universitaire de Limoges Dupuytren 2, Limoges, France.
出版信息
In Vivo. 2024 May-Jun;38(3):1451-1453. doi: 10.21873/invivo.13589.
BACKGROUND
Immunotherapy using immune checkpoint inhibitors is not devoid of immune-related adverse events (irAEs) including rheumatological conditions.
CASE REPORT
We report a rare case of a 47-year-old woman with metastatic melanoma who developed systemic scleroderma after initiating nivolumab. The patient displayed inflammatory arthralgias, morning stiffness, and classical cutaneous manifestations of the disease. Clinical evaluations also revealed carpal tunnel syndrome, cardiac involvement, and dyspnea. RNA-Polymerase III antibodies were positive. Nivolumab, an anti-PD-1 antibody, was considered as a potential trigger for this condition.
CONCLUSION
To our knowledge, this is the first case of nivolumab-induced systemic scleroderma in the context of melanoma described in the literature that fulfills the classification criteria of the disease. This case underscores the need for increased awareness of immune-related adverse events in patients receiving immune checkpoint inhibitors, emphasizing timely intervention and further research.
背景
免疫检查点抑制剂的免疫疗法并非没有免疫相关不良反应（irAEs），包括风湿性疾病。
病例报告
我们报告了一例罕见的 47 岁转移性黑色素瘤女性患者，在开始使用纳武单抗后出现系统性硬皮病。患者表现为炎性关节痛、晨僵和疾病的典型皮肤表现。临床评估还发现腕管综合征、心脏受累和呼吸困难。RNA 聚合酶 III 抗体阳性。抗 PD-1 抗体纳武单抗被认为是这种情况的潜在触发因素。
结论
据我们所知，这是文献中首例描述的黑色素瘤背景下纳武单抗诱导的系统性硬皮病病例，符合该疾病的分类标准。该病例强调了需要提高对接受免疫检查点抑制剂治疗的患者免疫相关不良反应的认识，强调及时干预和进一步研究。
Zotero 插件